GRAIL, Inc. (GRAL) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 Menlo Park, CA, 미국. 현재 CEO는 Robert Ragusa.
GRAL 을(를) 보유 IPO 날짜 2024-06-12, 1,000 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $2.07B.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
